His Highness Sheikh Hasher bin Maktoum bin Juma Al Maktoum officially opened the 31st Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT 2026) today. This prominent event stands as the largest of its kind in the Middle East and Africa, attracting numerous global pharmaceutical companies. Scheduled to be held at the Dubai World Trade Centre until August 27, the conference is expected to draw over 25,000 visitors from 85 countries.

Strong Participation from Industry Leaders

The inauguration saw the presence of distinguished guests, including His Excellency Dr. Alawi Alsheikh Ali, Director General of Dubai Health Authority, and His Excellency Dr. Amer Sharif, CEO of Dubai Health. High-profile figures such as His Excellency Ambassador Prof. Abdulsalam AlMadani, who serves as the Chairman of DUPHAT and the DUPHAT International Scientific Council, were also in attendance. The conference provides a critical platform for senior representatives from pharmaceutical manufacturers, suppliers, pharmacists, and other industry specialists, thereby fostering networking and collaboration.

Broad Range of Specialised Segments

DUPHAT 2026 showcases a diverse array of segments, including pharmaceuticals, parapharmaceuticals, technology, vitamins, and nutritional supplements. Alongside the main event, VITASHOW Dubai is highlighting the latest innovations in dietary supplements, thus offering a comprehensive view of the current market landscape. This year’s VITASHOW introduces the Dubai Nutrition Conference, aimed specifically at clinical nutrition, further enriching the scientific dialogue and educational offerings of the event.

In total, the conference features over 1,100 brands, 104 scientific sessions, and 12 workshops, as well as 400 scientific posters presented by aspiring university students, making it a hub of knowledge and innovation.

Commitment to Industry Growth

His Excellency Amb. Prof. Abdulsalam AlMadani emphasized that DUPHAT 2026 reflects the ongoing growth within the pharmaceutical industry. It serves as a vital forum where various stakeholders can engage, share insights, and explore partnerships. This year’s heightened international participation signifies the UAE’s emergence as a pivotal hub for pharmaceutical innovation and healthcare development.

The Emirates Drug Establishment (EDE) has officially backed DUPHAT 2026, reinforcing the event’s role as a platform for regulatory and industry collaboration. This support signifies the EDE’s commitment to fortifying the pharmaceutical sector through enhanced collaboration, regulatory development, and innovation.

Exploring Future Trends and Innovations

DUPHAT 2026 emphasizes the evolving landscape of the pharmaceutical sector, fostering dialogue on significant trends like regulatory transformation and technological innovations. The Pharma Leadership Forum is one of the key features, designed to facilitate conversations among industry leaders, government officials, and regulatory authorities.

This strategic dialogue aims to strengthen partnerships and prepare for future challenges in the pharmaceutical domain. By enabling industry stakeholders to explore the entire spectrum of pharmaceutical development—from research and manufacturing to marketing—DUPHAT positions itself as a critical player in shaping the future of healthcare solutions in the region.

As the UAE pharmaceutical market continues to grow, with projected revenues reaching $8 billion by 2033, it is clear that initiatives like DUPHAT 2026 are essential for fostering collaboration, advancing knowledge, and driving innovation across the sector. The event stands as a testament to the UAE’s commitment to remaining at the forefront of pharmaceutical advancements in an increasingly interconnected global market.